GGGeorge Gachara

George Gachara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


George Gachara has a total of 84 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Full-Genome Characterization of Hepatitis B Virus Among Asymptomatic Carriers in Kenya

    by Silvanos Opanda, George Gachara, Fred Wamunyokoli, Erick Kitangala, Kenfri Muchui, Timothy Mwasia, Maurice Wakwabubi, Wallace Bulimo

    Hepatitis B virus (HBV) infection remains a significant global public health concern. Data suggest that HBV genotypes/sub-genotypes and virulence-associated mutations can influence the natural history and treatment outcomes of HBV infection. However, the dearth of full-length HBV genome sequences in Kenya limits complete understanding of emerging variants and recombination events. Here, we sequenced and analyzed 165 HBV DNA whole-genome sequences from HBsAg-positive serum samples of voluntary blood donors across different geographic regions of Kenya between 2019 and 2023 to provide deeper insights into the virus’s genomic diversity, virulence-associated mutations, recombinations, and drug resistance profiles. Genomic analysis revealed a predominance of HBV genotype A in Kenya (77.0%), followed by genotype D (19.4%) and genotype E (3.6%) during the study period. Within genotype A, sub-genotype A1 predominated (99%), while A2 was a minority. Among genotype D, sub-genotype D7 was most common (97%), followed by D1 (3%). Recombination was detected in 4.2% of the sequenced isolates and involved genotype A/D, A/E, D/A, and D/E recombinant forms. None of the sequenced isolates harbored mutations linked to resistance to approved nucleos(t)ide analogues in the reverse transcriptase region of the polymerase gene. However, genetic variation associated with a higher risk of hepatocellular carcinoma (HCC), vaccine immune escape, and occult hepatitis B virus infection (OBI) were detected across genomic regions, including HCC-linked mutations G1896A in 81.3% (26/32; 95% CI: 63.6–92.8) of genotype D and 50% (3/6; 95% CI: 11.8–88.2) of genotype E isolates (FDR-adjusted p < 0.001); and G1899A in 17.0% (28/165; 95% CI: 11.6–23.6, FDR-adjusted p < 0.05) in the precore gene region of all isolates. Additionally, those present in the basal core promoter region included C1773T in 80.0% (132/165; 95% CI: 73.1–85.8, FDR-adjusted p < 0.001) and A1762T/G1764-double mutation in 29.1% (48/165; 95% CI: 22.3–36.7) of all isolates. Immune escape-linked amino acid variation within the “a” determinant of the major hydrophilic region (MHR) in the S gene region, included T131N in 99.2% (126/127; 95% CI: 95.7–100, FDR-adjusted p < 0.001) of genotype A and T126A/S in 16.7% (1/6; 95% CI, 0.4–64.1, FDR-adjusted p > 0.05) of genotype E isolates, while those related to occult-HBV infection (OBI) included P127H/L in 3.6% (6/165; 1.3–7.7, FDR-adjusted p < 0.001) of all isolates. Overall, our findings indicate that HBV genotype A (sub-genotype A1) predominates in Kenya, followed by genotypes D (sub-genotype D7) and E. Moreover, the detection of HBV variants harboring genetic markers associated with immune escape, occult hepatitis B (OBI), and liver disease complications highlights the need for public health countermeasures such as immunization of infants and scaling up of adult vaccination to reduce infections. Furthermore, wider integration of molecular real-time PCR testing into the national blood screening algorithm is advised to reduce the risk of horizontal transmission from asymptomatic HBV blood donors harboring occult HBV infection mutations and ensure the safety of blood and blood products.

  • Open Access

    Publisher Correction: Hepatitis C virus in Kenya: a 10-year systematic review

    by Patrick Okoti Aluora, George Gachara

  • Open Access

    Molecular characterization of hepatitis B virus genotypes A and D among inmates and blood donors in Northeastern Kenya

    by Vincent Bahati Odallo, Okoti P. Aluora, Wallace Bulimo, George Gachara

    Introduction: Hepatitis B virus (HBV) persists as a major global public health burden, with hyperendemic prevalence in sub-Saharan Africa. Populations with elevated exposure to percutaneous transmission risks, including incarcerated individuals and healthcare workers demonstrate heightened HBV susceptibility. Despite this, genomic data from Northeastern Kenya and Kenyan prison populations remain scarce. Objective: To characterize HBV genotypic diversity circulating in Northeastern Kenya, among low-risk (blood donors) and high-risk (prison inmates) populations. Methods: A cross-sectional investigation compared HBV seroprevalence and genotypes between incarcerated individuals (n = 130) and voluntary blood donors (n = 130) in Garissa County, Northeastern Kenya. Serum samples were subjected to Hepatitis B surface antigen (HBsAg) screening, PCR amplification of a 940-bp overlapping surface/polymerase gene, sequencing, and phylogenetic/recombination analyses of the resulting sequences. Results: Seroprevalence was higher among incarcerated individuals (5.4%, 7/130) than blood donors (3.1%, 4/130). Hepatitis B Virus DNA was detected in 22 samples which were all successfully sequenced. Genotype D dominated both cohorts (81.8%), while genotype A sub genotype A1 occurred exclusively in incarcerated participants (18.2%). All genotype D strains were recombinants: D/A (61%) and D/E (39%). Sequences are accessible in GenBank (accession numbers: PV816552–PV816573). Conclusions: This first genomic study of HBV in Kenyan prisons confirms incarcerated populations as high-risk. The predominance of genotype D—an unusual finding in this region and high recombinant frequency (100% of genotype D strains) underscore significant viral evolution. Expanded genomic surveillance is imperative to define HBV diversity, inform vaccine efficacy monitoring, guide screening policies and optimize control strategies in Northeastern Kenya.


  • Open Access

    Molecular characterization of hepatitis B virus genotype D and recombinant strains among inmates and blood donors in Northeastern Kenya

    by Vincent Bahati Odallo, Okoti P. Aluora, Wallace Bulimo, George Gachara

    Introduction: Hepatitis B virus (HBV) persists as a major global public health burden, with hyperendemic prevalence in sub-Saharan Africa. Populations with elevated exposure to percutaneous transmission risks—including incarcerated individuals and healthcare workers—demonstrate heightened HBV susceptibility. Despite this, genomic data from Northeastern Kenya and Kenyan prison populations remain scarce. Objective: To characterize HBV genotypic diversity circulating in Northeastern Kenya, among low risk (blood donors) and high-risk (prison inmates) populations. Methods: A cross-sectional investigation compared HBV seroprevalence and genotypes between incarcerated individuals (n = 130) and voluntary blood donors (n = 130) in Garissa County, Northeastern Kenya. Sample size was calculated using Casagrande’s formula for binomial comparison powered at 80% (α=0.05) to detect a ≥2-fold seroprevalence difference between cohorts. Serum samples underwent Hepatitis B surface antigen (HBsAg) screening, PCR amplification of a 940-bp overlapping surface/polymerase gene, sequencing, and phylogenetic/recombination analyses of the resulting sequences. Results: Seroprevalence was higher among incarcerated individuals (5.4%, 7/130) than blood donors (3.1%, 4/130). HBV DNA was detected in 22 samples. Genotype D dominated both cohorts (81.8%), while genotype A subgenotype A1 occurred exclusively in incarcerated participants (18.2%). All genotype D strains were recombinants: D/A (61%) and D/E (39%). Sequences are accessible in GenBank (accession numbers: PV816552 – PV816573 ). Conclusions: This first genomic study of HBV in Kenyan prisons confirms incarcerated populations as high-risk. The predominance of genotype D—a novel finding in this region—and high recombinant frequency (100% of genotype D strains) underscore significant viral evolution. Expanded genomic surveillance is imperative to define HBV diversity, inform vaccine efficacy monitoring, and optimize control strategies in Northeastern Kenya.

  • Open Access

    Hepatitis C virus in Kenya: a 10-year systematic review

    by Patrick Okoti Aluora, George Gachara


  • Open Access

    Prevalence of Post COVID-19 Condition among Healthcare Workers: Self-Reported Online Survey in Four African Countries, December 2021–January 2022

    by Hager Elnadi, Ahmad I. Al-Mustapha, Ismail A. Odetokun, AbdulAzeez Adeyemi Anjorin, Rasha Mosbah, Folorunso O. Fasina, Youssef Razouqi, Kwame Sherrif Awiagah, Jean Baptiste Nyandwi, Zuhal E. Mhgoob, et al.

    The impact of Post COVID-19 Condition (PCC) is ongoing despite the declaration that the 2019 COVID-19 pandemic has ended. In this study, we explore the prevalence of PCC among healthcare workers (HCWs) in four African Countries and its influence on their professional performance. This study was conducted as an online cross-sectional survey of healthcare workers from four African countries (Cameroon, Egypt, Nigeria, and Somalia) between the 20th of December 2021 to 12th of January 2022. We determined the prevalence of PCC based on the WHO case definition and assessed variables associated with a higher prevalence of PCC in these countries using univariable and multivariable logistic regression analyses. A total of 706 HCWs from four African countries were included in this survey. Most of the HCWs were aged between 18–34 years (75.8%, n = 535). Our findings showed that 19.5% (n = 138) of the HCWs had tested positive for SARS-CoV-2. However, 8.4% (n = 59) were symptomatic for COVID-19 but tested negative or were never tested. Two-thirds of the HCWs (66.4%, n = 469) have received a COVID-19 vaccine and 80.6% (n = 378) of those vaccinated had been fully vaccinated. The self-reported awareness rate of PCC among the HCWs was 16.1% (n = 114/706) whereas the awareness rate of PCC among COVID-19-positive HCWs was 55.3% (n = 109/197). The prevalence of PCC among HCWs was 58.8% (n = 116). These changes include the self-reported symptoms of PCC which included headache (58.4%, n = 115), fatigue (58.8%, n = 116), and muscle pain (39.6%, n = 78). Similarly, 30% (n = 59) and 20.8% (n = 41) of the HCWs reported the loss of smell and loss of taste long after their COVID-19 infection, respectively. Some HCWs (42%, n = 83) believed that their work performance has been affected by their ongoing symptoms of PCC. There was no significant difference in the prevalence of PCC among the vaccinated and unvaccinated HCWs (p > 0.05). Of the socio-demographic variables, age (older HCWs between 45–54 years; OR:1.7; 95% CI: 1.06, 10.59; p = 0.001) and location (Egypt; OR:14.57; 95% CI: 2.62, 26.76; p = 0.001) were more likely to have experienced PCC than other age groups and countries respectively. The study revealed a low prevalence of PCC among the surveyed HCWs. In addition, it observed the need for adequate medical and psychological support to HCWs with PCC and improved mass advocacy campaigns on PCC.


  • Open Access

    Public Health Surveillance for Adverse Events Following COVID-19 Vaccination in Africa

    by AbdulAzeez Adeyemi Anjorin, Ismail A. Odetokun, Jean Baptiste Nyandwi, Hager Elnadi, Kwame Sherrif Awiagah, Joseph Eyedo, Ajibola Ibraheem Abioye, George Gachara, Aala MohmedOsman Maisara, Youssef Razouqi, et al.

    Local, national, and international health agencies have advocated multi-pronged public health strategies to limit infections and prevent deaths. The availability of safe and effective vaccines is critical in the control of a pandemic. Several adverse events have been reported globally following reception of different vaccines, with limited or no data from Africa. This cross-sectional epidemiological study investigated adverse events following COVID-19 vaccination in Africans from April–June, 2021 using a structured online questionnaire. Out of 1200 participants recruited, a total of 80.8% (n = 969) respondents from 35 countries, including 22 African countries and 13 countries where Africans live in the diaspora, reported adverse events. Over half of the vaccinees were male (53.0%) and frontline healthcare workers (55.7%), respectively. A total of 15.6% (n = 151) reported previous exposure to SARS-CoV-2, while about one-fourth, 24.8% (n = 240), reported different underlying health conditions prior to vaccination. Fatal cases were 5.1% (n = 49), while other significant heterogenous events were reported in three categories: very common, common, and uncommon, with the latter including enlarged lymph nodes 2.4% (n = 23), menstrual disorder 0.5% (n = 5), and increased libido 0.2% (n = 2). The study provided useful data for concerned authorities and institutions to prepare plans that will address issues related to COVID-19 vaccines.


  • Open Access

    Characterization of occult hepatitis B in high-risk populations in Kenya

    by Kiptoon Beatrice Jepkemei, Missiani Ochwoto, Ken Swidinsky, Jacqueline Day, Henok Gebrebrhan, Lyle R McKinnon, Anton Andonov, Julius Oyugi, Joshua Kimani, George Gachara, et al.

    Occult hepatitis B infection (OBI) is defined as the presence of hepatitis B virus (HBV) DNA in the liver or serum in the absence of detectable HBV surface antigen (HBsAg). OBI poses a risk for the development of cirrhosis and hepatocellular carcinoma. The prevalence of OBI in Kenya is unknown, thus a study was undertaken to determine the prevalence and molecular characterization of OBI in Kenyan populations at high risk of HBV infection. Sera from two Nairobi cohorts, 99 male sex workers, primarily having sex with men (MSM-SW), and 13 non-MSM men having HIV-positive partners, as well as 65 HBsAg-negative patients presenting with jaundice at Kenyan medical facilities, were tested for HBV serological markers, including HBV DNA by real-time PCR. Positive DNA samples were sequenced and MSM-SW patients were further tested for hepatitis C virus (HCV) infection. Of the 166 HBsAg-negative samples tested, 31 (18.7%; 95% confidence interval [CI] 13.5–25.3) were HBV DNA positive (i.e., occult), the majority (20/31; 64.5%) of which were HBV core protein antibody positive. HCV infection was not observed in the MSM-SW participants, although the prevalence of HBsAg positivity was 10.1% (10/99; 95% CI 5.6–17.6). HBV genotype A was predominant among study cases, including both HBsAg-positive and OBI participants, although the data suggests a non-African network transmission source among MSM-SW. The high prevalence of HBV infection among MSM-SW in Kenya suggests that screening programmes be instituted among high-risk cohorts to facilitate preventative measures, such as vaccination, and establish entry to treatment and linkage to care.


  • Open Access

    Assessing antigenic drift and phylogeny of influenza A (H1N1) pdm09 virus in Kenya using HA1 sub-unit of the hemagglutinin gene

    by Silvanos Opanda, Wallace Bulimo, George Gachara, Christopher Ekuttan, Evans Amukoye

    Influenza A (H1N1) pdm09 virus emerged in North America in 2009 and has been established as a seasonal strain in humans. After an antigenic stasis of about six years, new antigenically distinct variants of the virus emerged globally in 2016 necessitating a change in the vaccine formulation for the first time in 2017. Herein, we analyzed thirty-eight HA sequences of influenza A (H1N1) pdm09 strains isolated in Kenya during 2015–2018 seasons, to evaluate their antigenic and molecular properties based on the HA1 sub-unit. Our analyses revealed that the A (H1N1) pdm09 strains that circulated in Kenya during this period belonged to genetic clade 6B, subclade 6B.1 and 6B.2. The Kenyan 2015 and 2016 isolates differed from the vaccine strain A/California/07/2009 at nine and fourteen antigenic sites in the HA1 respectively. Further, those isolated in 2017 and 2018 correspondingly varied from A/Michigan/45/2015 vaccine strain at three and fifteen antigenic sites. The predicted vaccine efficacy of A/California/07/2009 against Kenyan 2015/2016 was estimated to be 32.4% while A/Michigan/45/2015 showed estimated vaccine efficacies of 39.6% - 41.8% and 32.4% - 42.1% against Kenyan 2017 and 2018 strains, respectively. Hemagglutination-inhibition (HAI) assay using ferret post-infection reference antiserum showed that the titers for the Kenyan 2015/2016 isolates were 2–8-fold lower compared to the vaccine strain. Overall, our results suggest the A (H1N1) pdm09 viruses that circulated in Kenya during 2015/2016 influenza seasons were antigenic variants of the recommended vaccine strains, denoting sub-optimal vaccine efficacy. Additionally, data generated point to a swiftly evolving influenza A (H1N1) pdm09 virus in recent post pandemic era, underscoring the need for sustained surveillance coupled with molecular and antigenic analyses, to inform appropriate and timely influenza vaccine update.


  • Open Access

    HHV-8 Seroprevalence and Genotype Distribution in Africa, 1998–2017: A Systematic Review

    by Elizabeth M. Etta, Doyinmola P. Alayande, Lufuno G. Mavhandu-Ramarumo, George Gachara, Pascal O. Bessong

    Human herpes virus type 8 (HHV-8) is the causative agent of Kaposi’s sarcoma (KS). We systematically reviewed literature published between 1998 and 2017, according to the PRISMA guidelines, to understand the distribution of HHV-8 infection in Africa. More than two-thirds (64%) of studies reported on seroprevalence and 29.3% on genotypes; 9.5% were on both seroprevalence and genotypes. About 45% of African countries had data on HHV-8 seroprevalence exclusively, and more than half (53%) had data on either seroprevalence or genotypes. Almost half (47%) of the countries had no data on HHV-8 infection. There was high heterogeneity in the types of tests and interpretation algorithms used in determining HHV-8 seropositivity across the different studies. Generally, seroprevalence ranged from 2.0% in a group of young children in Eritrea to 100% in a small group of individuals with KS in Central African Republic, and in a larger group of individuals with KS in Morocco. Approximately 16% of studies reported on children. Difference in seroprevalence across the African regions was not significant (95% CI, χ2 = 0.86; p = 0.35), although specifically a relatively significant level of infection was observed in HIV-infected children. About 38% of the countries had data on K1 genotypes. K1 genotypes A, A5, B, C, F and Z occurred at frequencies of 5.3%, 26.3%, 42.1%, 18.4%, 5.3% and 2.6%, respectively. Twenty-three percent of the countries had data for K15 genotypes, and genotypes P, M and N occurred at frequencies of 52.2%, 39.1%, and 8.7%, respectively. Data on HHV-8 inter-genotype recombinants in Africa are scanty. HHV-8 may be endemic in the entire Africa continent but there is need for a harmonized testing protocol for a better understanding of HHV-8 seropositivity. K1 genotypes A5 and B, and K15 genotypes P and M, from Africa, should be considered in vaccine design efforts.